

## **BÜHLMANN Laboratories launch fecal Calprotectin test on Roche cobas® system**

Schönenbuch, 11. February 2020

BÜHLMANN Laboratories announce a new partner channel agreement with Roche Diagnostics for the launch and distribution of their BÜHLMANN fCAL® turbo test. The test - which aids in the diagnosis of inflammatory diseases in the gastrointestinal tract - will be distributed by Roche Diagnostics and used directly on the cobas® c501/c502 chemical analyzer systems in Europe.

As a neutrophilic inflammation marker, fecal Calprotectin plays an important role in the differentiation of functional diseases like Irritable Bowel Syndrome (IBS) from organic diseases like Inflammatory Bowel Disease (IBD). It is also used for monitoring of the inflammatory burden in diagnosed IBD patients, particularly for drug therapy monitoring of patients. The cost-effective and non-invasive diagnostic test helps to avoid unnecessary colonoscopies. Its application helps improve the quality of life of patients, supports the treating physician in clinical decision-making and contributes to savings for the health care system.

The direct application of the fCAL turbo on cobas® c501/c502 analyzers will be a very powerful method for modern core labs that are looking for fast and reliable results with little hands-on time. The combination with the BÜHLMANN developed CALEX® Cap extraction device for fast and reliable sample preparation is a significant milestone to break free from cumbersome and laborious manual methods of the past.

Dr. Thomas Hafen, CEO of BÜHLMANN says: “Combining the most powerful fecal calprotectin test in the market and the unique CALEX® extraction method with the cobas® systems will offer significant advantages for everybody. We are particularly proud to offer innovative health care solutions which improve the life of patients and help to manage health care expenses.”

After the launch in Europe, a step-by-step expansion is planned to North America, Latin America, Asia and Middle East and the rest of the world.

The BÜHLMANN fCAL® turbo and CALEX® Cap received its approval in the European markets in 2015, in Canada, Brazil, Australia and many other major markets in 2016 and in the US in 2019.

### **About BÜHLMANN Laboratories AG**

BÜHLMANN Laboratories AG focuses since 1976 on the development, manufacturing and world-wide promotion of in-vitro diagnostics. BÜHLMANN is known for outstanding product quality, excellent after-sales services, and scientific innovation. Among others, BÜHLMANN offers IBDoc® for patient self-testing of calprotectin levels. The Quantum Blue® menu offers rapid, quantitative and near patient testing of calprotectin as well as Infliximab and Adalimumab assays for TDM. For more information, please visit [www.buhlmannlabs.ch](http://www.buhlmannlabs.ch).